A Comparison of CPT Versus ART Versus WL
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03384706 |
|
Recruitment Status :
Recruiting
First Posted : December 27, 2017
Last Update Posted : October 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Posttraumatic Stress Disorder | Behavioral: Cognitive Processing Therapy (CPT) Behavioral: Accelerated Resolution Therapy (ART) | Not Applicable |
Objective(s): The primary aim of this study is to examine the effectiveness of two treatments for the symptoms of Posttraumatic Stress Disorder (PTSD) with a no therapy, wait list control condition. The two treatments are Cognitive Processing Therapy (CPT) as compared to Accelerated Resolution Therapy (ART). Additional related symptoms of depression, anger, sleep, and physical health will also be assessed. The study will involve both civilians and veterans seeking outpatient therapy for PTSD. Data will be obtained via clinician structured interviews and self-report measures.
Research Design: Participants will be recruited from the Cincinnati VA Medical Center, Trauma Recovery Center (TRC), and at the University of Cincinnati (UC) Health Stress Center located in Cincinnati, Ohio. All eligible participants will be randomized to receive CPT, ART, or Wait List (WL) condition. For participants who are randomized to the WL condition, following a period of seven weeks will be randomized into one of the two active treatment conditions, CPT or ART. Participants in the two active treatment conditions will complete an assessment at pre-treatment, post-treatment, 3 month, and 1 year follow-up.
Methodology: Participants will include 280 males and females ages 18 and older who meet criteria for PTSD (or subthreshold PTSD). The investigators will contact potential participants to determine eligibility for the study assessing inclusionary and exclusionary criteria. All eligible participants will then be asked to complete a pre-treatment assessment prior to being assigned their study treatment (CPT or ART or WL). Participants will receive a full course of outpatient CPT or ART depending on their assigned study treatment. Once the participant and treating clinician determine that therapy has been fully completed, participants will complete a post-treatment assessment. Follow-up assessments will then be completed 3-months and 1-year following the completion of therapy.
At each assessment participants will be asked to complete a series of self- and clinic-reported measures that include assessments of PTSD symptoms, depression, general mental health, pain, sleep habits, and health care utilization.
Findings: Not applicable at this time.
Clinical Relationships: The investigators anticipate that understanding the comparative effectiveness between CPT and ART therapies will provide necessary information for care provided to civilians and veterans suffering from PTSD.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 280 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | This study will examine the effectiveness of Cognitive Processing Therapy (CPT) as compared to Accelerated Resolution Therapy (ART) and a Waitlist (WL) control using a Randomized, Cross-Over Design. 280 participants will be randomly assigned to ART, CPT or WL. Upon completion of the WL condition, participants will be re-randomized to ART or CPT. |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | The assessors will remain blind to treatment condition throughout the study. |
| Primary Purpose: | Treatment |
| Official Title: | A Comparison of Cognitive Processing Therapy (CPT) Versus Accelerated Resolution Therapy (ART) Versus Wait List (WL) |
| Actual Study Start Date : | September 6, 2017 |
| Estimated Primary Completion Date : | December 31, 2022 |
| Estimated Study Completion Date : | December 31, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Cognitive Processing Therapy (CPT)
PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
|
Behavioral: Cognitive Processing Therapy (CPT)
CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world. CPT will be conducted in 5-15, 60 minute sessions held once or twice a week. |
|
Experimental: Accelerated Resolution Therapy (ART)
PTSD Psychotherapy
|
Behavioral: Accelerated Resolution Therapy (ART)
ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking. ART will be conducted in 5-15, 60 minute sessions held once or twice a week. |
|
No Intervention: Wait List Control
Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
|
- PTSD symptom severity [ Time Frame: Through study completion, an average of 15 months ]Combined Clinician-Administered PTSD Scale for DSM-IV and DSM-5 (CAPS-IV/CAPS-V)
- Depression symptom severity [ Time Frame: Through study completion, an average of 15 months ]Patient Health Questionnaire-9 (PHQ-9)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- May have posttraumatic stress disorder (PTSD)
Exclusion Criteria:
- Meet criteria for unmedicated bipolar, mania, or unmedicated psychotic disorders
- Meet criteria for a substance use disorder requiring detoxification treatment
- Have active suicidal or homicidal intent with (a) plan(s) and (a) means
- Have a medical condition that will interfere with twice weekly therapy sessions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03384706
| Contact: Laura A Gilliam, PhD | 513-861-3100 ext 6226 | Laura.Gilliam@va.gov | |
| Contact: Erica L Birkley, PhD | 513-558-1919 | birkleea@ucmail.uc.edu |
| United States, Ohio | |
| University of Cincinnati | Recruiting |
| Cincinnati, Ohio, United States, 45219 | |
| Contact: Laura A Gilliam, PhD 513-861-3100 ext 6226 Laura.Gilliam@va.gov | |
| Contact: Erica L Birkley, PhD 513-558-1919 birkleea@ucmail.uc.edu | |
| Principal Investigator: Kathleen M Chard, PhD | |
| Cincinnati VA Medical Center | Recruiting |
| Cincinnati, Ohio, United States, 45220 | |
| Contact: Laura A Gilliam, PhD 513-861-3100 ext 6226 Laura.Gilliam@va.gov | |
| Contact: Erica L Birkley, PhD 513-558-1919 birkleea@ucmail.uc.edu | |
| Principal Investigator: Kathleen M Chard, PhD | |
| Principal Investigator: | Kathleen M Chard, PhD | Cincinnati VA Medical Center; University of Cincinnati |
Documents provided by Kathleen Chard, University of Cincinnati:
| Responsible Party: | Kathleen Chard, Director, University of Cincinnati |
| ClinicalTrials.gov Identifier: | NCT03384706 |
| Other Study ID Numbers: |
2017-1590 |
| First Posted: | December 27, 2017 Key Record Dates |
| Last Update Posted: | October 18, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
posttraumatic stress disorder (PTSD) Clinical Trial Psychotherapy Assessment Effectiveness |
|
Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Trauma and Stressor Related Disorders Mental Disorders |

